Defunct Company
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
474
NCT03401346
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 19, 2017
Completion: Dec 6, 2017
NCT03541356
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
Phase: Phase 2
Start: May 8, 2018
Completion: Jun 11, 2019
NCT03557333
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
Phase: Phase 3
Start: Jul 13, 2018
Completion: Mar 17, 2020
NCT03624322
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
Start: Aug 5, 2018
Completion: Oct 3, 2018
NCT05163717
INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD
Start: Jun 23, 2022
Completion: Apr 24, 2023